Live Breaking News & Updates on Alliditas

Stay informed with the latest breaking news from Alliditas on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Alliditas and stay connected to the pulse of your community

Calliditas Therapeutics : Termination of Open Market Sale Agreement - Form 6-K

Termination of Open Market Sale Agreement

On June 7, 2023, Calliditas Therapeutics AB notified Jefferies LLC of its decision to terminate the Open Market Sale AgreementSM,... | June 8, 2023

United-states , American , Company-registration-statement-on-form , Company-american-depositary , Open-market-sale , Calliditas-therapeutics , Sales-agreement , American-depositary-shares , Common-shares , Securities-act , Nasdaq-global-select-market

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM, April 28, 2023 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned

Stockholm , Sweden , United-states , American , Swedish , Jakob-grunditz , Fred-driscoll , Fredrik-johansson , Monte-carlo , Molly-henderson , Elmar-schnee , Henrik-stenqvist

2022: Successful transformation into a commercial stage company - Form 6-K

2022: Successful transformation into a commercial stage company

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for... | February 23, 2023

China , Sweden , Japan , United-states , Stockholm , United-kingdom , Switzerland , Japanese , Chinese , American , Marie-galay , Kidney-international

Calliditas launches first IgA kidney disease education campaign

Calliditas is running the first educational campaign for the disease amid the first-ever IgAN Awareness Day.

Chronic-kidney-disease , Wareness-campaigns , Ocial-media , Igital-marketing , Alliditas , Arpeyo , Are-diseases , Utoimmune-disease , Pharma , Ierce-pharma-homepage , Marketing

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

STOCKLHOLM, May 19, 2022 /PRNewswire/ -- The meeting was held in accordance with sections §§ 20 and 22 of the Act (2022:121) on temporary exceptions to facilitate the execution of general meetings

Sweden , United-states , Stockholm , American , Hilde-furberg , Elmar-schnee , Lennart-hansson , Henrik-stenqvist , Anna-svanberg , Mikael-widell , Molly-henderson , European-commission

Number of shares and votes in Calliditas Therapeutics

STOCKHOLM, April 29, 2022 /PRNewswire/ -- During April, Calliditas Therapeutics AB (publ) has allotted 830,586 common shares within the company's warrant program issued in 2018. Thus, as of

Sweden , United-states , Stockholm , American , Swedish , Mikael-widell , European-medicines-agency , Calliditas-therapeutics , Swedish-financial-instruments-trading , Nasdaq-stockholm , American-depositary-shares , Nasdaq-global-select-market

FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO (budesonide) to Reduce Proteinuria in IgA Nephropathy

- TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression

Sweden , United-states , Stockholm , United-kingdom , Stanford , Leicestershire , America , Andrew-udell , Marie-galay , Bonnie-schneider , Richard-philipson , Villa-baca